I-Mab (IMAB) – Weekly Analyst Rating Changes


Several brokerages have updated their stock price recommendations and targets. I-Mab (NASDAQ: IMAB) over the past few weeks:

  • 05/31/2022 – I-Mab has been upgraded by analysts at Zacks Investment Research from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 05/31/2022 – I-Mab has had its price target lowered by Needham & Company LLC analysts from $85.00 to $72.00. They now have a “buy” rating on the stock.
  • 05/31/2022 – I-Mab has had its price target lowered by HC Wainwright analysts from $80.00 to $70.00. They now have a “buy” rating on the stock.
  • 05/27/2022 – I-Mab has had its price target lowered by analysts at Piper Sandler from $80.00 to $35.00.
  • 05/25/2022 – I-Mab has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 04/05/2022 – I-Mab has been downgraded by analysts at Zacks Investment Research from a ‘Hold’ rating to a ‘Sell’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 04/28/2022 – I-Mab has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 04/22/2022 – I-Mab has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 04/15/2022 – I-Mab has been upgraded by Zacks Investment Research analysts from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 08/04/2022 – I-Mab has been upgraded by analysts at Zacks Investment Research from a ‘sell’ rating to a ‘hold’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “
  • 02/04/2022 – I-Mab has been downgraded by analysts at Zacks Investment Research from a ‘hold’ rating to a ‘sell’ rating. According to Zacks, “I-Mab is a clinical-stage biopharmaceutical company. It engages in the discovery, development and commercialization of biological products to treat diseases with significant unmet medical needs, in particular cancers and autoimmune diseases. I-Mab is based in SHANGHAI, China. “

IMAB shares traded down $0.28 on Wednesday, hitting $8.42. 21,848 shares of the stock traded in hands, compared to its average volume of 968,495. I-Mab has a 52-week low of $8.12 and a 52-week high of $85.40. The company has a 50-day simple moving average of $13.56 and a two-hundred-day simple moving average of $28.98.

Institutional investors and hedge funds have been buying and selling stocks recently. American International Group Inc. bought a new position in I-Mab during the third quarter worth $29,000. Eaton Vance Management bought a new position in I-Mab during the third quarter worth $54,000. Acadian Asset Management LLC bought a new stock position in I-Mab in Q1 worth $65,000. Penserra Capital Management LLC increased its stake in I-Mab shares by 32.4% in the third quarter. Penserra Capital Management LLC now owns 960 shares of the company worth $69,000 after purchasing an additional 235 shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its stake in I-Mab shares by 6,607.4% in Q3. Advisor Group Holdings Inc. now owns 1,811 shares of the company worth $131,000 after purchasing an additional 1,784 shares in the last quarter. 96.17% of the shares are held by institutional investors.

I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and commercializes biological products to treat cancer and autoimmune diseases. It is developing Felzartamab, a CD38 antibody that is in phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with red blood cell-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative and autoimmune colitis.

Featured articles



Get news and reviews for I-Mab Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for I-Mab and related companies with MarketBeat.com’s free daily email newsletter.

About Catriona

Check Also

Why major streamers are reassessing the way they do business amid recession fears | Features

The past few months have not been easy for streamers. The specter of a recession …